Fibralign set to bring new device option for secondary lymphedema

Jun 26, 2014

A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale, California) developed BioBridge, a surgical device designed to support the formation of new functional lymphatic vessels.

The company has completed a large animal study to validate the technology and is now preparing for a clinical study. Fibralign was voted the winner of the annual MedTech Innovator competition by an audience at the 22nd annual medical device conference hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR). The company won prizes valued at $150,000, including $100,000 in cash provided by RCT Ventures, $25,000 in cash provided by Johnson & Johnson Development Corporation, and $25,000 worth of lab space at Janssen Labs.

Medical Device Daily | Today’s Headlines

A young company developing a product to address secondary lymphedema, a chronic disease with no cure, stole the show at a venture competition held during a recent medical device conference. Working with Stanford University (Stanford, California), Fibralign (Sunnyvale, California) developed BioBridge, a surgical device designed to support the formation of new functional lymphatic vessels.

The company has completed a large animal study to validate the technology and is now preparing for a clinical study. Fibralign was voted the winner of the annual MedTech Innovator competition by an audience at the 22nd annual medical device conference hosted by law firm Wilson Sonsini Goodrich & Rosati (WSGR). The company won prizes valued at $150,000, including $100,000 in cash provided by RCT Ventures, $25,000 in cash provided by Johnson & Johnson Development Corporation, and $25,000 worth of lab space at Janssen Labs.

Read more.

Fibralign Announces CE Mark Approval for BioBridge®

Fibralign Announces CE Mark Approval for BioBridge®

European approval for novel device supporting surgical treatment of lymphedema September 14, 2020 (Union City, CA) – Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first...

read more
Fibralign Announces Strategic Partnership with Terumo

Fibralign Announces Strategic Partnership with Terumo

Exclusive agreement for Terumo to market and distribute Fibralign’s BioBridge in Japan June 02, 2020 06:00 AM Eastern Daylight Time UNION CITY, Calif.--(BUSINESS WIRE)--Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced...

read more